Evidence map›Paper›PMID 40952530›Full record

ReviewJournal of computer-aided molecular design2025

Prospects for the structure‒function evolution of SARS-CoV-2 main protease inhibitors.

Anatoliy A Bulygin, Nikita A Kuznetsov

Abstract readReview
PubMed Publisher
In one paragraph

Review in Journal of computer-aided molecular design, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Anatoliy A BulyginInstitute of Chemical Biology and Fundamental Medicine, Siberian Branch (SB) of RAS, Novosibirsk, Russia. abulygin@niboch.nsc.ru.
Nikita A KuznetsovInstitute of Chemical Biology and Fundamental Medicine, Siberian Branch (SB) of RAS, Novosibirsk, Russia. Nikita.Kuznetsov@1bio.ru.

Funding

Russian state #121112900214-2
6 · The paper itself

Abstract

The COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become the third case of widespread coronavirus infection. Together with the other two viruses, the SARS-CoV-2 virus is highly pathogenic, and some strains have a mortality rate of more than 1%. Moreover, it has become clear that coronaviruses mutate quite often, which reduces the effectiveness of available vaccines and forces the regular creation of new ones. The main viral protease M

Indexed as

Antiviral AgentsCoronavirus 3C ProteasesCOVID-19 Drug TreatmentProtease InhibitorsSARS-CoV-2COVID-19HumansLactamsLeucineMolecular Dynamics SimulationNitrilesProlineStructure-Activity Relationship3C-like proteinase, SARS-CoV-2Antiviral AgentsCoronavirus 3C ProteasesLactamsLeucinenirmatrelvirNitrilesProlineProtease InhibitorsInhibitor bindingMain proteaseMolecular dynamicsSARS-CoV-2

Identifiers

PMID40952530

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.